Vivimed Labs has inked a definitive agreement with Strides Shasun to grow its presence in the US finished dosage formulation (FDF) business segment. This 50-50 JV in India, will house the company’s US FDA inspected FDF facility in Alathur, Tamil Nadu, and the 50-50 JV in Singapore will house its current portfolio of ANDAs.
The company believes the JV partnership with Strides Shasun offers its portfolio of products the synergies from Strides Shasun’s existing front end in the US market. This coupled with Vivimed’s product development pipeline for the US offers the JV a strong opportunity to grow its footprint aggressively.
MAP India is the exclusive advisor to Vivimed Labs for the above transaction with Strides Shasun.
